drugset / Trial / NCT03324685

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685

Phase 1 Completed 36 enrolled Biogen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the effect of multiple doses of a uridine diphosphate glucuronosyltransferases (UGT)-inducing oral contraceptive (OC) regimen (ethinyl estradiol and levonorgestrel) on the PK of BIIB074 at steady state; evaluate the effect of multiple doses of BIIB074 on the pharmacokinetics(PK) of an OC regimen (ethinyl estradiol and levonorgestrel) at steady state. The secondary objective of this study is to evaluate the safety and tolerability of BIIB074 when administered alone and when coadministered with a UGT-inducing OC regimen containing ethinyl estradiol and levonorgestrel and to evaluate the effect of a UGT-inducing OC regimen (ethinyl estradiol and levonorgestrel) on the PK of the M13, M14, and M16 metabolites of BIIB074.

Timeline

Start
2017-11-11
Primary completion
2018-03-15
Completion
2018-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 150 ug Oral
Subject Vixotrigine Small molecule 150 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications

No indication recorded.